The ESMO TAT Congress 2027 is a leading international meeting for early‑phase clinical development and translational research in targeted therapies. Bringing together global experts from academia, clinical practice and industry, the congress offers an in‑depth look at emerging anticancer agents, novel combinations and biomarker‑driven strategies that are transforming outcomes for patients with cancer.

For academic researchers and clinicians

ESMO TAT 2027 is the place to discuss hypothesis-generating data, explore innovative trial designs and understand how emerging agents fit into evolving treatment pathways.

Oncologists, clinicians, scientists, translational researchers, pharmacologists, and statisticians will find a programme tailored to the realities of early phase development in routine practice.

From mechanism of-action to first-in-human dosing, from biomarker selection to resistance and toxicity management, the congress supports you in bringing promising new options to patients more efficiently and safely.

For pharma, biotech and industry partners

For professionals in pharma, biotech and diagnostics, ESMO TAT 2027 offers a unique opportunity to position pipelines within the broader targeted therapies landscape. Meet key opinion leaders, trial investigators and academic partners, and gain insight into clinical needs, patient populations and competitive contexts that shape development strategies.

Dedicated sessions will address challenges in early-phase development, including dose optimisation, combinations, biomarker strategy, regulatory expectations and pathways to pivotal studies.

Discover. Transform. Advance.